deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02122172

Afatinib in Advanced Refractory Urothelial Cancer

Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Distal Urethral Cancer Proximal Urethral Cancer Recurrent Bladder Cancer Recurrent Urethral Cancer Stage III Bladder Cancer Stage III Urethral Cancer Stage IV Bladder Cancer Stage IV Urethral Cancer Ureter Cancer
Interventions afatinib dimaleate laboratory biomarker analysis
Updated 17 times since 2017 Last updated: Apr 24, 2025 Started: Sep 13, 2017 Primary completion: Apr 4, 2024 Completion: Apr 4, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unable to meet accrual goal after several years

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Listed as NCT02122172, this PHASE2 trial focuses on Distal Urethral Cancer and Proximal Urethral Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 17 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~May 2023 · 19 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – present · 16 months · monthly snapshot

Change History

17 versions recorded

  1. May 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — May 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Sep 2023 — Jun 2024 [monthly]

    Recruiting PHASE2

▶ Show 12 earlier versions

  1. May 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  2. Oct 2021 — May 2023 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Nov 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  6. Nov 2018 — Nov 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  8. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  9. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations